Pharmacyte Biotech Inc  

(Public, OTCMKTS:PMCB)   Watch this stock  
+0.0008 (0.92%)
Nov 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.09 - 0.09
52 week 0.07 - 0.26
Open 0.09
Vol / Avg. 616,836.00/1.66M
Mkt cap 65.05M
P/E     -
Div/yield     -
EPS -0.01
Shares 743.43M
Beta 1.81
Inst. own 0%

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -27.23% -125.74%
Return on average equity -33.98% -145.91%
Employees 4 -
CDP Score - -


12510 Prosperity Dr Ste 310
SILVER SPRING, MD 20904-1643
United States - Map
+1-917-5952850 (Phone)
+1-917-5952851 (Fax)

Website links


Pharmacyte biotech, Inc., formerly Nuvilex, Inc. is a clinical-stage biotechnology company. The Company focuses on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Company uses this technology as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are developed. The Company's treatment for pancreatic cancer involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or cancer-killing form. The Company is also engaged in developing treatments for cancer-based upon chemical constituents of the Cannabis plant, known as cannabinoids. In addition to developing treatments for pancreatic and other solid tumor cancers, it is developing a treatment for Type I diabetes and Type II insulin-dependent diabetes.

Officers and directors

Kenneth L. Waggoner Chairman of the Board, President, Chief Executive Officer, General Counsel
Age: 65
Robert Bowker President of Knock-Out Technologies, Inc.
Age: 65
Gerald W. Crabtree Ph.D. Chief Operating Officer, Director
Age: 73
Walter H. Gunzburg Chief Scientific Officer
Thomas Liquard Director